当前位置：
X-MOL 学术
›
Gene Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
An overview of development in gene therapeutics in China.
Gene Therapy ( IF 5.1 ) Pub Date : 2020-06-11 , DOI: 10.1038/s41434-020-0163-7 Dawei Wang 1 , Kang Wang 2 , Yujia Cai 3
更新日期：2020-06-11
Gene Therapy ( IF 5.1 ) Pub Date : 2020-06-11 , DOI: 10.1038/s41434-020-0163-7 Dawei Wang 1 , Kang Wang 2 , Yujia Cai 3
Affiliation
After setbacks related to serious adverse events 20 years ago, gene therapy is now coming back to the central stage worldwide. In the past few years, gene therapy has shown astonishing efficacy against genetic diseases and cancers. In history, China carried out the world’s second gene therapy clinical trial in 1991 for hemophilia B and approved the world’s first gene therapy product—Gendicine—in 2003. In recent years, numerous efforts have been made on gene editing. Here, we reviewed the past of gene therapy in China and highlighted recent advances. We also discussed the regulations and future perspectives of gene therapy in China.
京公网安备 11010802027423号